Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment This retrospective ...
Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study We analyzed 2,974 newly ...
Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Initial LDCT orders were placed ...
Circulating tumor DNA (ctDNA) assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that ...
Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?
What's in the Syringe—Or Isn't: Defining Perioperative Supportive Care Interventions for Improved Surgical Outcomes Among Older Adults With Cancer The following represents disclosure information ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Of 922 screened titles, Lam et al 7 identified only 11 studies that met the inclusion criteria of randomized controlled trials of nonpharmacologic, noninterventional supportive care interventions ...
Erratum: Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue ...
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma Anti–vascular endothelial growth factor therapy enhances PD-1 ...
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback